Entheon Biomedical Terminates Business Combination with Nutravisor, Receives CAD $350,000 Settlement
Key Insights
Entheon Biomedical Corp. terminated its definitive business combination agreement with Nutravisor Inc (search)., ending a proposed reverse takeover transaction originally announced in January 2026.
The biotechnology company focused on addiction (search) and substance use disorder treatments received a CAD $175,000 cash payment and CAD $175,000 in settlement shares from Nutravisor.
Trading in Entheon's common shares remains halted on the Canadian Securities Exchange, with the company promising updates on trading resumption in due course.
Entheon Biomedical Corp. announced the termination of its business combination agreement with Nutravisor Inc (search)., effectively ending a proposed reverse takeover that would have significantly restructured the biotechnology company focused on addiction (search) treatments.
The definitive business combination agreement, originally signed on January 19, 2026, and amended on March 9, 2026, outlined a "three-cornered" amalgamation that would have resulted in Nutravisor acquiring Entheon through a reverse takeover structure. Under the terminated agreement, Entheon would have acquired all outstanding common shares and securities of Nutravisor in exchange for Entheon securities.
Settlement Terms and Financial Impact
As part of the termination agreement, Nutravisor provided Entheon with a comprehensive settlement package totaling CAD $350,000. The settlement includes an immediate cash payment of CAD $175,000 and an additional CAD $175,000 in settlement shares.
The settlement shares will be calculated based on a deemed issue price equal to the greater of CAD $0.50 per share or 80% of the price per common share in Nutravisor's next liquidity event. These shares will be issued either as Nutravisor common shares or shares of the resulting issuer in connection with a future go-public transaction.
Operational Implications
The termination eliminates several planned corporate actions that were contingent on the business combination's completion. Entheon will not proceed with the previously announced share consolidation, name change, or other restructuring steps that were part of the proposed transaction.
Trading in Entheon's common shares remains suspended on the Canadian Securities Exchange. The company stated it will provide updates regarding the resumption of trading "in due course," though no specific timeline was provided.
Company Background
Entheon Biomedical Corp. operates as a biotechnology research and development company with a focus on treating addiction (search) and substance use disorders (search). The company trades on multiple exchanges under the symbols CSE: ENBI, OTCQB: ENTBF, and FSE: 1XU.
Timothy Ko serves as the company's CEO, President, and Director, leading the organization's strategic direction in the addiction (search) treatment space.
Forward-Looking Considerations
The company acknowledged several risks associated with the settlement terms, including the possibility that Nutravisor may fail to deliver the settlement cash or issue the promised settlement shares. Management emphasized that forward-looking statements regarding the settlement and trading resumption are subject to various business, economic, and regulatory uncertainties.